Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net sales	$ 16,747	$ 14,240	$ 12,682
Cost of products sold	5,257	4,345	3,956
Gross profit	11,490	9,896	8,727
Operating expenses:
Selling, general and administrative expenses	5,984	5,190	4,520
Research and development expenses	1,615	1,414	1,323
Royalty expense	33	46	47
Amortization expense	856	828	803
Intangible asset impairment charges	386	58	132
Contingent consideration net expense (benefit)	(5)	58	35
Restructuring net charges (credits)	16	69	24
Litigation-related net charges (credits)	0	(111)	173
Loss (Gain) on Disposal of Businesses and Assets	0	0	22
Operating expenses	8,887	7,553	7,078
Operating income (loss)	2,603	2,343	1,649
Other income (expense):
Interest expense	(305)	(265)	(470)
Other, net	(16)	(93)	(38)
Income (loss) before income taxes	2,282	1,985	1,141
Income tax expense (benefit)	436	393	443
Net income (loss)	1,846	1,592	698
Dividends, Preferred Stock, Stock	0	(23)	(55)
Net income (loss) attributable to noncontrolling interests	(8)	(1)	0
Net income (loss) attributable to Boston Scientific common stockholders	$ 1,853	$ 1,570	$ 642
Net income (loss) per common share — basic	$ 1.26	$ 1.08	$ 0.45
Net income (loss) per common share — diluted	$ 1.25	$ 1.07	$ 0.45
Weighted-average shares outstanding
Basic	1,471,500	1,453,000	1,430,500
Diluted	1,485,900	1,463,500	1,439,700